June 30, 2026

Low Weight Linked to Severe Pediatric COVID

Brazilian pediatric intensive care unit study found underweight status was associated with respiratory complications, longer hospitalization, and mortality among critically ill patients with COVID-19.

Conexiant

June 18, 2026

FDA Expands CAPVAXIVE Pediatric Use

Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.

Conexiant

June 18, 2026

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

Conexiant

June 15, 2026

Does Sedative Choice Shape Later Cognition?

Researchers examined long-term cognitive outcomes among children who received ICU sedation for acute respiratory failure.

Conexiant

June 11, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Conexiant

June 05, 2026

Youth Vaping Is "Predictable" by Design

Product engineering, not individual choice, is driving adolescent nicotine dependence, researchers argue.

Conexiant

June 03, 2026

Measles Renews Focus on Vaccine Waivers

“And when one of these measles cases ends up in a low-immunization community, that's when the ember really has a chance to expand and become a wildfire.”

Kff Health News

June 03, 2026

Measles Renews Focus on Vaccine Waivers

“And when one of these measles cases ends up in a low-immunization community, that's when the ember really has a chance to expand and become a wildfire.”

Kff Health News

June 02, 2026

FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure

Phase 3 data showed a 67% reduction in symptomatic infection among exposed household contacts who tested negative at baseline.

Conexiant

May 29, 2026

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

Conexiant